SEC Form 4 · accession 0001193125-26-271300
Parabilis Medicines, Inc. · PBLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexis Borisy
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 15, 2026 · 5:17 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001657677
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 11, 2026 | C | 105,414 | — | A | 105,414 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series F Preferred StockF1 | — | Jun 11, 2026 | C | 162,221 | A | — | — | Common Stock | 105,414 | 0 | D |
Explanation of responses
- F1Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.